Search research articles
Contact Us
Filters
Showing results (151-160 of 161) with videos related to
Page
of 17
Sort By:
Biorxiv : the Preprint Server for Biology
|
July 10, 2023
Genomic and ecological factors shaping specialism and generalism across an entire subphylum
Dana A Opulente, Abigail Leavitt LaBella, Marie-Claire Harrison, et al.
Science (New York, N.Y.)
|
April 25, 2024
Genomic factors shape carbon and nitrogen metabolic niche breadth across Saccharomycotina yeasts
Dana A Opulente, Abigail Leavitt LaBella, Marie-Claire Harrison, et al.
Leukemia
|
March 28, 2026
Myeloproliferative neoplasms with concomitant chronic myeloid leukemia are associated with TKI resistance and poor outcomes
Laura Li Gagnon, Andrea Duminuco, Fabio Stagno, et al.
Blood
|
August 8, 2024
Proposals for revised International Working Group-European LeukemiaNet criteria for anemia response in myelofibrosis
Ayalew Tefferi, Giovanni Barosi, Francesco Passamonti, et al.
Haematologica
|
August 6, 2013
Comparison of placebo and best available therapy for the treatment of myelofibrosis in the phase 3 COMFORT studies
Ruben A Mesa, Jean-Jacques Kiladjian, Srdan Verstovsek, et al.
Nature Genetics
|
June 9, 2025
Chromothripsis-associated chromosome 21 amplification orchestrates transformation to blast-phase MPN through targetable overexpression of DYRK1A
Charlotte K Brierley, Bon Ham Yip, Giulia Orlando, et al.
Nature Communications
|
April 8, 2015
Genetic variation at MECOM, TERT, JAK2 and HBS1L-MYB predisposes to myeloproliferative neoplasms
William Tapper, Amy V Jones, Robert Kralovics, et al.
Blood Advances
|
November 14, 2022
CNL and aCML should be considered as a single entity based on molecular profiles and outcomes
Gonzalo Carreño-Tarragona, Alberto Álvarez-Larrán, Claire Harrison, et al.
Leukemia
|
January 8, 2021
High mortality rate in COVID-19 patients with myeloproliferative neoplasms after abrupt withdrawal of ruxolitinib
Tiziano Barbui, Alessandro Maria Vannucchi, Alberto Alvarez-Larran, et al.
Blood Cancer Journal
|
February 10, 2021
Among classic myeloproliferative neoplasms, essential thrombocythemia is associated with the greatest risk of venous thromboembolism during COVID-19
Tiziano Barbui, Valerio De Stefano, Alberto Alvarez-Larran, et al.
Page
of 17
Search research articles
Search
Showing results (151-160 of 161) with videos related to
Sort By:
Page
of 17
Biorxiv : the Preprint Server for Biology
|
July 10, 2023
Genomic and ecological factors shaping specialism and generalism across an entire subphylum
Dana A Opulente, Abigail Leavitt LaBella, Marie-Claire Harrison, et al.
Science (New York, N.Y.)
|
April 25, 2024
Genomic factors shape carbon and nitrogen metabolic niche breadth across Saccharomycotina yeasts
Dana A Opulente, Abigail Leavitt LaBella, Marie-Claire Harrison, et al.
Leukemia
|
March 28, 2026
Myeloproliferative neoplasms with concomitant chronic myeloid leukemia are associated with TKI resistance and poor outcomes
Laura Li Gagnon, Andrea Duminuco, Fabio Stagno, et al.
Blood
|
August 8, 2024
Proposals for revised International Working Group-European LeukemiaNet criteria for anemia response in myelofibrosis
Ayalew Tefferi, Giovanni Barosi, Francesco Passamonti, et al.
Haematologica
|
August 6, 2013
Comparison of placebo and best available therapy for the treatment of myelofibrosis in the phase 3 COMFORT studies
Ruben A Mesa, Jean-Jacques Kiladjian, Srdan Verstovsek, et al.
Nature Genetics
|
June 9, 2025
Chromothripsis-associated chromosome 21 amplification orchestrates transformation to blast-phase MPN through targetable overexpression of DYRK1A
Charlotte K Brierley, Bon Ham Yip, Giulia Orlando, et al.
Nature Communications
|
April 8, 2015
Genetic variation at MECOM, TERT, JAK2 and HBS1L-MYB predisposes to myeloproliferative neoplasms
William Tapper, Amy V Jones, Robert Kralovics, et al.
Blood Advances
|
November 14, 2022
CNL and aCML should be considered as a single entity based on molecular profiles and outcomes
Gonzalo Carreño-Tarragona, Alberto Álvarez-Larrán, Claire Harrison, et al.
Leukemia
|
January 8, 2021
High mortality rate in COVID-19 patients with myeloproliferative neoplasms after abrupt withdrawal of ruxolitinib
Tiziano Barbui, Alessandro Maria Vannucchi, Alberto Alvarez-Larran, et al.
Blood Cancer Journal
|
February 10, 2021
Among classic myeloproliferative neoplasms, essential thrombocythemia is associated with the greatest risk of venous thromboembolism during COVID-19
Tiziano Barbui, Valerio De Stefano, Alberto Alvarez-Larran, et al.
Page
of 17